HC Wainwright Issues Positive Forecast for DiaMedica Therapeutics (NASDAQ:DMAC) Stock Price

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) had its price objective raised by equities research analysts at HC Wainwright from $10.00 to $12.00 in a report released on Friday,Benzinga reports. The brokerage presently has a "buy" rating on the stock. HC Wainwright's target price would indicate a potential upside of 202.72% from the company's current price.

DiaMedica Therapeutics Trading Up 0.9%

Shares of NASDAQ:DMAC traded up $0.03 on Friday, hitting $3.96. 42,567 shares of the company were exchanged, compared to its average volume of 108,449. The stock's 50 day moving average price is $3.92 and its 200 day moving average price is $4.70. The firm has a market capitalization of $169.98 million, a P/E ratio of -6.11 and a beta of 1.17. DiaMedica Therapeutics has a 1-year low of $3.19 and a 1-year high of $6.82.

DiaMedica Therapeutics (NASDAQ:DMAC - Get Free Report) last released its earnings results on Tuesday, May 13th. The company reported ($0.18) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.18). During the same period in the previous year, the business earned ($0.14) earnings per share. On average, equities analysts predict that DiaMedica Therapeutics will post -0.59 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in DMAC. Balyasny Asset Management L.P. bought a new position in shares of DiaMedica Therapeutics in the 4th quarter valued at about $79,000. Raymond James Financial Inc. acquired a new position in shares of DiaMedica Therapeutics during the 4th quarter valued at $83,000. Bank of Montreal Can purchased a new stake in shares of DiaMedica Therapeutics in the fourth quarter valued at about $84,000. Cornerstone Wealth Management LLC bought a new position in DiaMedica Therapeutics during the first quarter worth about $62,000. Finally, Dimensional Fund Advisors LP raised its stake in shares of DiaMedica Therapeutics by 14.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 19,339 shares of the company's stock worth $105,000 after acquiring an additional 2,380 shares in the last quarter. Institutional investors own 10.12% of the company's stock.

DiaMedica Therapeutics Company Profile

DiaMedica Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.